MedTrace Logo

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

NCT00754104 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2011-01-19

No results posted yet for this study

Summary

Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors

Conditions

Interventions

DRUG

ABT-869

0.25 mg/kg. daily.

DRUG

Tarceva

150mg, daily.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Abbott

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754104 on ClinicalTrials.gov